Cobolimab

DB16372InvestigationalProtein Based Therapies

Cobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants).

Mechanism: Pharmacologically active on Hepatitis A virus cellular receptor 2
Curator reviewed
Code names: TSR-022 · WBP-296A

Resolves to

Compound

UNII3K5H4TX2KPCAS2022215-65-0

Targets

Q8TDQ0HAVCR2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cobolimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account